The promising medication, retatrutide, is generating significant buzz in the United Kingdom regarding a possible option for obesity. Created by Lilly, it merges the effects of different glucagon-like peptide-1 (GLP-1) receptor agonists and a GIP receptor agonist, trying to better control hunger and increase metabolism. Initial clinical trials have